Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$0.16
EPS est.
$0.15
EPS surprise
+8.89%
1-day move
-4.57%
Stevanato Group reported better-than-expected earnings per share, beating consensus estimates. However, the stock fell by 4.57% on the day, which may reflect concerns about revenue performance or broader market conditions. Investors will be looking for more clarity in future reports.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.16 | $0.15 | +8.89% |
| Revenue | N/A | $298M | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Stevanato Group S.p.A. is a key player in the health care sector, specializing in life sciences tools and services. The company focuses on providing innovative solutions for the pharmaceutical and biotechnology industries, which are critical for developing and delivering medications.
Last quarter
In Q1-2026, Stevanato Group reported an EPS of $0.13, surpassing estimates by 5.94%. However, the stock fell by 5.11% the following day, indicating some market disappointment despite the earnings beat.
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
+6.58%
Avg 1-day reaction
+3.11%
Analysts expect Stevanato Group to report an EPS of $0.15 and revenue of $298M for Q2-2026. The market is keenly watching for any signs of growth or challenges in the current economic environment.
Bull case
If Stevanato can exceed the EPS estimate and show strong revenue growth, it may indicate robust demand for its products, leading to a positive market reaction.
Bear case
Conversely, if the company misses its earnings or revenue targets, it could signal underlying issues in demand or operational challenges, potentially leading to a significant drop in stock price.
Key metrics to watch
EPS
$0.15Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue
$298MRevenue figures will provide insight into the company's sales performance and demand for its products and services.
The print will turn on these.
Q1
Will the company achieve an EPS of at least $0.15?
This figure is crucial as it reflects the company's ability to manage costs and generate profit, which will heavily influence investor sentiment.
Q2
What is the revenue outlook for the upcoming quarters?
Understanding revenue trends will help gauge demand for Stevanato's products and services, impacting future growth expectations.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may underestimate the potential for revenue growth driven by increased demand in the pharmaceutical sector, which could lead to a stronger-than-expected performance.
Supporting evidence
The company's recent product innovations may not be fully reflected in analyst models.
Options pricing suggests a higher expected volatility, indicating that investors anticipate significant news or changes.
Historical performance shows that the company has a solid track record of beating earnings expectations.
Key risk
If revenue growth exceeds $300M, it could challenge the current bearish sentiment and shift expectations positively.
Pre-commit to what would confirm each case.
The market is weighing the company's ability to maintain profitability and revenue growth amidst economic uncertainties.
Bull confirmed if
An EPS of $0.15 or higher, coupled with revenue exceeding $298M, would confirm strong operational performance.
Bear confirmed if
An EPS below $0.14 and revenue below $293M would suggest potential challenges in demand or operational execution.
What the market is pricing for the move.
Implied Move
±34.08%
Historical Avg
±8.5%
The options market is pricing in a substantial move, suggesting that investors expect significant volatility around the earnings announcement.
Options are pricing ±34.1% while STVN has averaged ±8.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
36.1%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$293,453.50
13,649 sh
1 insider
Net
$293,453.50
Net selling
Most Active Insiders· 1 open-market trade
$293,453.50
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
98.68%
of float
Insider
1.80%
of float
Holders
166
institutions
Top Holders· as of Jun 2026
Conestoga Capital Advisors, LLC
7,007,613 sh · $136.2M
2.31%
-17.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Stevanato beats expectations, history suggests the stock could see a modest increase of around 1.1% on the first day, confirming positive momentum.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance from management.
Miss
A miss could lead to a significant drop, with historical patterns indicating an average decline of around 13.55% following earnings misses.
The lines on the call that would change the story.
Recent Transactions
Sep 28, 2026 · @ $21.50
13,649 sh
$293,453.50
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Neuberger Berman Group, LLC
5,622,269 sh · $109.3M
1.86%
25.6%
Times Square Capital Management, LLC
3,474,641 sh · $67.5M
1.15%
-0.4%
Van Berkom & Associates Inc.
2,969,220 sh · $57.7M
0.98%
1636.5%
Artisan Partners Limited Partnership
2,601,598 sh · $50.6M
0.86%
13.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.